Successful Retreatment With ADOC Chemotherapy in Relapsed Thymic Carcinoma: Experiences in Two Cases

The optimal second-line chemotherapeutic regimen for thymic carcinoma remains uncertain and predictive factors for the response have not been identified. We encountered two cases of relapsed thymic carcinoma with recurrence 1.5 and 8 years after initial response to cisplatin/doxorubicin/vincristine/...

Descripción completa

Detalles Bibliográficos
Autores principales: Nomura, Yayoi, Koizumi, Tomonobu, Kitaguchi, Akihiro, Horiuchi, Toshimichi, Kanda, Shintarou, Yamamoto, Hiroshi, Hanaoka, Masayuki, Kubo, Keishi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2012
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649833/
https://www.ncbi.nlm.nih.gov/pubmed/29147275
http://dx.doi.org/10.4021/wjon435w
Descripción
Sumario:The optimal second-line chemotherapeutic regimen for thymic carcinoma remains uncertain and predictive factors for the response have not been identified. We encountered two cases of relapsed thymic carcinoma with recurrence 1.5 and 8 years after initial response to cisplatin/doxorubicin/vincristine/cyclophosphamide (ADOC) chemotherapy. Both cases were successfully retreated with ADOC. Our observations suggest that relapsed thymic carcinoma occurring a long treatment-free time from the initial response may be sensitive to the previous chemotherapy. We described two cases of relapsed thymic carcinoma successfully retreated with ADOC chemotherapy. Both patients had partial response to initial ADOC and long disease free times.

Ejemplares similares